Clinical Trial Update: Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the onset of efficacy of dimethyl fumarate (BG00012) in relapsing-remitting multiple sclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Dimethyl fumarate (Dimethyl fumarate)

Snippet

Sponsor: Biogen | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 4 | Status: WITHDRAWN